40 selected startups participated in the Nordic Life Science Days, the largest life science partnering conference in the Nordic countries, in Malmö on September 28-29, 2022. Together with these 40 teams, MyoPax was privileged to present our innovative technologies and business concepts.
A jury of investors evaluated the pitches in terms of degree of innovation, impact and investment readiness.
We are very proud that MyoPax was awarded the first prize of the NLSInvest Awards.
The runner-up, Asgard Therapeutics, is a Swedish biotech company exploring the application of direct in vivo cell reprogramming for cancer immunotherapy.
Further reading: https://nordiclifescience.org/the-winner-of-nlsinvest-awards-has-been-announced/
Our video feature
„Chelsea Ranger, chair of the NLSINvest Committee and senior advisor to SwedenBIO, said: “Both of the winning companies had confident and engaging pitches that thoroughly showcased the unmet medical needs and the patient populations they serve.“